Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis

High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC).

[1]  Xuehua Piao,et al.  A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis , 2017, Evidence-based complementary and alternative medicine : eCAM.

[2]  B. Feagan,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[3]  S. Travis,et al.  Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.

[4]  L. Stitt,et al.  Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials , 2015, Alimentary pharmacology & therapeutics.

[5]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[6]  G. Sjøgaard,et al.  Does training frequency and supervision affect compliance, performance and muscular health? A cluster randomized controlled trial. , 2015, Manual therapy.

[7]  A. Bitton,et al.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.

[8]  M. Vandervoort,et al.  Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.

[9]  Mamoru Watanabe,et al.  Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study , 2013, Inflammatory bowel diseases.

[10]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[11]  O. Dewit,et al.  Randomised clinical trial: once‐ vs. twice‐daily prolonged‐release mesalazine for active ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.

[12]  C. Beauchemin,et al.  Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database , 2013, BMC Gastroenterology.

[13]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[14]  Andre Charlett,et al.  The Feedback Intervention Trial (FIT) — Improving Hand-Hygiene Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled Trial , 2012, PloS one.

[15]  L. Bazzano,et al.  Long‐term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10‐year retrospective cohort from the veterans affairs healthcare system , 2012, Alimentary pharmacology & therapeutics.

[16]  N. Ntoumanis,et al.  Communication style and exercise compliance in physiotherapy (CONNECT). A cluster randomized controlled trial to test a theory-based intervention to increase chronic low back pain patients’ adherence to physiotherapists’ recommendations: study rationale, design, and methods , 2012, BMC Musculoskeletal Disorders.

[17]  D. Gillespie,et al.  One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis , 2011, Inflammatory bowel diseases.

[18]  M. Sumner,et al.  Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database , 2011, Digestive Diseases and Sciences.

[19]  A. Vcev,et al.  Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[20]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[21]  M. Campieri,et al.  Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.

[22]  T. Stijnen,et al.  Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[24]  S. Kane,et al.  Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial , 2008, Patient preference and adherence.

[25]  Martin L. Brown,et al.  Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. , 2008, Clinical therapeutics.

[26]  Xun Chen,et al.  Choosing the analysis population in non‐inferiority studies: per protocol or intent‐to‐treat , 2006, Statistics in medicine.

[27]  M. J. Shale,et al.  Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[28]  D. Huo,et al.  A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[30]  R. Levy,et al.  Increasing patient adherence to gastroenterology treatment and prevention regimens , 1999, American Journal of Gastroenterology.

[31]  R. Newcombe,et al.  Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.

[32]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[33]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[34]  E. Gracely,et al.  Impact of multiple comparisons in randomized clinical trials. , 1987, The American journal of medicine.

[35]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.

[36]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[38]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[39]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[40]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[41]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[42]  D. Hosmer,et al.  Goodness of fit tests for the multiple logistic regression model , 1980 .